The XPD Lys751Gln Polymorphism has Predictive Value in Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy: a Systemic Review and Meta-analysis

Abstract

Background: The predictive value of the xeroderma pigmentosum group D (XPD) Lys751Gln polymorphism regarding clinical outcomes of patients with colorectal cancer (CRC) receiving oxaliplatin-based chemotherapy has been evaluated in numerous published studies, but the results remain inconclusive. Therefore, we performed a meta-analysis to determine the precise role of the XPD Lys751Gln polymorphism in this clinical situation and optimize individual chemotherapy. Materials and Methods: A multiple search strategy was used to identify eligible studies. Pooled odds ratios (ORs), generalized odds ratio (ORG) and their 95% confidence intervals (CIs) were used to estimate the objective response, while hazard ratios (HRs) with 95%CIs were used for progression-free survival (PFS) and overall survival (OS). Results: A total of 17 studies including 2,286 patients met the inclusion criteria. Overall, the XPD 751Gln allele was associated with a non-significant reduced objective response to oxaliplatin-based chemotherapy in all patients or in the Asian and Caucasian subgroups.

Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic Review

“…Our findings for ERCC1 rs11615 and XPD rs13181 are supported in four meta-analyses (Yin et al, 2011;Qian et al, 2014;Ma et al, 2015;Shahnam et al, 2016). The other biomarkers have not been studied as extensively.…”

A Comprehensive Evaluation of the Association between Polymorphisms in XRCC1, ERCC2, and XRCC3 and Prognosis in Hepatocellular Carcinoma: A Meta-Analysis

“…Previous research has shown that the wild-type genotype AA is associated with a higher DNA repair capacity as compared to that of the CC genotype in the rs13181 polymorphism [26]. Qian et al suggested that the ERCC2 rs13181 A>C polymorphism has prognostic value in patients with colorectal cancer undergoing oxaliplatin-based chemotherapy [27]. A meta-analysis demonstrated that the rs13181 A>C and rs1799793 G>A polymorphisms are significantly correlated with the response to chemotherapy for patients with osteosarcoma [28].…”

Correlation analysis between polymorphism of GSTP1, XPD and XRCC1 gene in esophageal carcinoma patients and treatment efficiency of cisplatin chemo-therapy

“…Xeroderma pigmentosum group D (XPD) gene facilitates DNA repair by denaturing damaged site. Previous findings showed the close relationship between SNP of XPD gene at 751 st locus ISSN 0970-938X www.biomedres.info and the sensitivity to platinum based drugs [15][16][17]. Moreover, study has found that Glutathione S-Transferase P1 (GSTP1) activity can be down-regulated by SNP of GSTP1 gene at 105 th locus, thus weakening platinum drug sensitivity [18,19].…”